Shareprice
06 Nov 2025

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide A/S issue warrants to board members, executive management and employees

Regulatory


November 3, 2025

Copenhagen, Denmark, 3 November 2025 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that it has issued 199,000 warrants to members of the board directors, members of the executive management and employees, based on the approved incentive program from 9 February 2021.

Today, the Board of Directors of FluoGuide has exercised its authorization to issue new warrants by issuing 199,000 warrants. The warrants are issued as part of the remuneration of the individuals. All warrants are issued free of charge.

In general, FluoGuide issue warrants to ensure alignment of interests between the Company’s employees, management, board of directors and shareholders. The Company believes that the issuance of warrants will strengthen the achievement of FluoGuide’s success to the benefit of patients with cancer and shareholders.

The warrants are issued in accordance with FluoGuide’s authorization in Clause 3.1.1 and Clause 3.2.1 of the Articles of Association as adopted by the shareholders acting in general meeting and the warrant program specified in Appendix 1 and 2 of the Articles of Association.

Each warrant confers the right to subscribe for (1) one new share in FluoGuide of nominal DKK 0.1. The exercise price is fixed at SEK 38 per share of nominal DKK 0.1, corresponding to 95% of the closing price of the Company’s shares on 3 November 2025. The warrants issued shall only vest and be exercisable after three years of employment following the warrant grant.

The warrants represent a total dilution corresponding of 1.4% of the current share capital, if vested and exercised and a total dilution corresponding to 1.2% of the share capital once the shares from the announced directed issue have been issued. The warrant program is the sixth warrant program to FluoGuide’s employees and management.
 
Vested warrants may be exercised in two annual exercise periods of two weeks following publication of respectively the Annual Report and the Interim half-year report. Warrants that have not been exercised 3 November 2035 at the latest, will lapse automatically.
 
FluoGuide accounts under the IFRS regulation and the theoretical market value of one newly issued warrant is SEK 21.76 corresponding to SEK 2,956,458 for all warrants issued. The calculation is based on the Black-Scholes model. The key assumptions for the Black Scholes calculation are a share price of SEK 38, a warrant exercise price of SEK 38, volatility of 57.70%, and a risk-free interest rate of 2.22%. The detailed terms of all warrants issued by the Company can be found in the Articles of Association on the Company’s website under Governance – FluoGuide A/S, following registration with the Danish Business Authorities.